Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity and Impact of 13-valent Pneumococcal Conjugate Vaccine in Alaskan Native Children.

NCT00743652 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00743652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00743652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity and Impact of 13-valent Pneumococcal Conjugate Vaccine in Alaskan Native Children.
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2009
Completion date
September 30, 2010
Enrollment
373 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

13-valent pneumococcal vaccine, pneumococcal disease